Segura-Rivera R, Brindis-Zavaleta M, Ortiz-Hidalgo C

Language: Spanish
References: 12
Page: 247-252
PDF size: 437.25 Kb.

ABSTRACT

Background: Aberrant CD20 expression in extranodal NK/T-cell lymphoma, nasal type is an extremely rare event and represents a diagnostic challenge.
Clinical case: A 54-year-old woman with a CD20-positive extranodal NK/T-cell lymphoma nasal type. Patient presented with a destructive right nasal lesion. The biopsy showed a polymorphic lymphoid infiltrate with angiocentricity and angiodestruction, resulting in necrosis, apoptosis, and ulceration. Immunohistochemical analysis demonstrated diffuse and strong positive staining for CD3ε, CD56, TIA-1 and membranous CD20, but the neoplastic cells stained negative for other B-cell markers (CD79a and PAX-5). The tumor cells were focally positive for LMP-1, but the nuclei were diffusely positive for EBER (Epstein-Barr virus-encoded RNA) in-situ hybridization.
Conclusions: It is interesting that some lymphomas may express both surface proteins of T and B-cells, but the underlying mechanism remains unknown.

REFERENCES

1. Tse E, Kwong YL. NK/T-cell lymphomas. Best Pract Res Clin Haematol 2019; 32: 253-261. doi: 10.1016/j. beha.2019.06.005

2. Quintanilla-Martínez L, Preffer F, Rubin D, Ferry JA, Harris NL. CD20+ T-cell lymphoma. Neoplastic transformation of a normal t-cell subset. Am J Clin Pathol 1994; 102: 483-489. doi: 10.1093/ajcp/102.4.483

3. Huang Y, Chen S, Wei R, Guo X, Yang X, Cao Q, Yang Y, Yun J. CD20-positive extranodal NK/T cell lymphoma: clinicopathologic and prognostic features. Virchows Arch 2020; 20. Online ahead of print doi: 10.1007/s00428-020-02776-x

4. Montes-Mojarro IA, Kim WY, Fend F, Quintanilla. Martínez L. Epstein-Barr virus positive T and NK-cell lymphoproliferations: Morphological features and differential diagnosis. Semin Diagn Patho 2020; 37: 32-46. doi:10.1053/j. semdp.2019.12.004

5. Chan JK, Quintanilla-Martinez L, Ferry JA. Extranodal NK/Tcell lymphoma, nasal type. En: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, editors. WHO classification of tumours of haematopoietic and lymphoid Tissues. Lyon: International Agency for Research on Cancer; 2017; 368-71.

6. Chena Q, Yuanb S, Sunc H, Pengc L, CD3+CD20+ T cells and their roles in human diseases. Hum Immunol. 2019; 80: 191-194. doi.org/10.1016/j.humimm.2019.01.001

7. Safdari Y, Ahmadzadeh V, Farajnia S. CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies. Investig New Drugs 2016; 34: 497- 512. doi: 10.1007/s10637-016-0349-4

8. Gupta N, Nasim M, Spitzer SG, Zhang X. Primary central nervous system T-cell lymphoma with aberrant expression of CD20 and CD79a: a diagnostic pitfall. Int J Surg Pathol 2017; 25: 599-603. doi: 10.1177/1066896917714325

9. Hultin LE, Hausner MA, Hultin PM, Giorgi JV. CD20 (Pan-B cell) antigen is expressed at a low level on a subpopulation of human T. Cytometry 1993; 14: 196-204. doi: 10.1002/ cyto.990140212

10. Haddad R, Guardiola P, Izac B, Thibault C, Radich J, Delezoide AL, Baillou C, Lemoine FM, Gluckman JC, Pflumio F, Canque B. Molecular characterization of early human T/NK and B lymphoid progenitor cells in umbilical cord blood. Blood 2004; 104: 3918-3926. doi: 10.1182/blood-2004-05-1845

11. Yamaguchi M, Oguchi M, Suzuki R. Extranodal NK/T-cell lymphoma: Updates in biology and management strategies. Best Pract Res Clin Haematol 2018; 31: 315-321. doi: 10.1016/j.beha.2018.07.002

12. Rahemtullah A, Longtine JA, Harris NL, Dorn M, Zembowicz A, Quintanilla-Fend L, Preffer FI, Ferry JA. CD20+ T-cell lymphoma: clinicopathologic analysis of 9 cases and a review of the literature. Am J Surg Pathol 2008; 32: 1593-1607. doi: 10.1097/PAS.0b013e31817d7452